CD34+ cell engraftment, ex vivo expansion, and malignant cell depletion following immunomagnetic selection.

This review describes the published preclinical and clinical data on the use of a manual or semiautomated immunomagnetic selection device, termed the Isolex system. Preclinical evaluation of hematopoietic progenitor cells (CD34+ cells) selected from bone marrow, peripheral blood leukapheresis products, and umbilical cord blood is reviewed with respect to differentiation (CFU-GM, BFU-E, and CFU-GEMM formation) and proliferation. The purities and yields of CD34+ cell products from clinical trials performed since 1994 are presented along with data on malignant cell depletion.

The contribution of animal models to the development of treatments for hematologic recovery following myeloablative therapy: a review.

This review describes the role that animal models have played in the development of clinical procedures for growth factor and hematopoietic cell therapies following high-dose cancer chemotherapy, radiotherapy or both. Data are discussed describing animal models that add to the understanding of human hematopoiesis, including myeloid and lymphoid lineage localization and in vivo maturation. Finally, current animal models of cytokine and cell therapies are presented in the context of their contributions to early clinical trials and future therapies.

Comparison of binding specificity and the function of two human IgM anti-lipid A monoclonal antibodies.

The interactions of two anti-lipid A monoclonal antibodies (mAb)--HA-1A and SdJ5-1.17.15--with their antigenic sites on lipid A, were compared using a dot-blot assay and lipid A structural analogues, as well as lipid A-high-density lipoprotein (HDL) complexes.

Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat.

Two human monoclonal antibodies, directed against the type a and type b flagellar proteins of Pseudomonas aeruginosa, inhibited bacterial motility in vitro specifically and in a concentration-dependent manner. In order to determine if this decreased bacterial motility was associated with a decreased pathogenicity, the ability of these human antiflagellar monoclonal antibodies to attenuate P. aeruginosa-induced pneumonia in the rat was assessed.

Inhibition of lipopolysaccharide-associated endotoxin activities in vitro and in vivo by the human anti-lipid A monoclonal antibody SdJ5-1.17.15.

The present study evaluated the effect of a novel anti-lipid A monoclonal antibody, termed SdJ5, on the in vitro production of tumor necrosis factor alpha (TNF-alpha) and interleukin-1 beta by endotoxin- or lipopolysaccharide (LPS)-challenged human peripheral blood mononuclear cells (hPBMC). In addition, the present study determined whether SdJ5 could neutralize the in vivo toxicity of LPS. SdJ5, at a concentration equal to or greater than 3 micrograms/ml, specifically inhibited TNF-alpha and interleukin-1 beta production by hPBMC stimulated with every type of LPS and lipid A assessed.

Lipopolysaccharide epitope specificity and binding cross reactivity of the human IgM anti-lipid A monoclonal antibody SdJ5-1.17.15.

The binding properties and specificity of the SdJ5-1.17.15 (SdJ5) human IgM monoclonal antibody (mAb), prepared against S.

The effects of plastic bag extracts prepared in either mouse serum or phosphate-buffered saline with ethanol on mouse splenic cells.

Chemicals leached from plastic blood bags are potentially immunogenic when introduced parenterally into humans. The experiments reported here represent an attempt to sensitize B6C3F1 mice to parenteral injections of solutions used to extract potentially immunogenic material from plastic blood bags. Mice were given intraperitoneal injections: blood bag extracts prepared from phosphate-buffered saline and ethanol; mouse red cells stored in extract solution; or blood bag extracts prepared from mouse serum.

Effect of metabolic inhibitors on the ability of human T lymphocytes to form active T rosettes.

The effect of various cellular metabolic inhibitors on the active T rosette formation of human peripheral blood lymphocytes with sheep red blood cells (SRBC) was studied. Cytochalasin B greatly inhibited SRBC rosette formation. However, colchicine, mytomycin C, cyclohexamide, and sodium azide had no effect.

Active T rosette formation of human T lymphocytes after stimulation with lectins.

The effect of fourteen plant lectins on human peripheral blood lymphocytes in rosette formation with sheep red blood cells (SRBC) was examined. Among the lectins used, phytohemagglutinin (PHA), lens culinalis (LCH), wheat germ agglutinin (WGA), and ricinus communis I (RCAI) showed a significant increase in active T rosette counts when the results were compared with the effect of other lectins. This enhancement in active T rosette forming cells is found within one hour after the treatment with lectin and is dependent upon the concentration of lectin.